Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML

opportunity-to-license-or-acquire-es-3000-an-orphan-drug-for-cml-and-aml

Oct 27, 2026

Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML

opportunity-to-license-or-acquire-es-3000-an-orphan-drug-for-cml-and-aml

Oct 27, 2026

Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML

opportunity-to-license-or-acquire-es-3000-an-orphan-drug-for-cml-and-aml

Oct 27, 2026



Escend Therapeutics (www.escendpharma.com) is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug indications. ES-3000 is an orally bioavailable small molecule (FW ~600 Da) with a unique mechanism of action and established clinical safety. ES-3000 ablates leukemic stem cells as it reduces β-catenin by inhibition of CaMKIIγ activity. Loss of b-catenin impairs the renewal of both CML and AML stem cells.

Sage represents Escend in its efforts to develop a strategic alliance for the further development of its ES-3000 oncology drug. We are pleased to attach an Executive Summary and non-confidential Information Memorandum outlining the partnering opportunity with Escend and ES-3000.

Escend’s lead program is focused on chronic myeloid leukemia (CML) in blast crisis or with suboptimal responses to the standard of care, which is about a third of 87,000 CML patients living with the disease in the US. There will be an estimated 120,000 patients by 2022, when market approval is expected. Given a 30% market penetration and an average cost of $100,000/yr/patient for drugs in this indication, ES-3000 could have upon approval potential annual revenue of $1.2 billion.

Six US provisional patent applications have been filed and freedom-to-operate analysis conducted for ES-3000. Escend’s IP focuses on methods of use and compositions of matter for ES-3000 or analogs for the treatment of leukemic stem cells, cancer stem cells and precancerous stem cells; and methods of use for ES-3000 and other β-catenin inhibitors as immune checkpoint inhibitor conditioning agents.

Orphan drug designation has been received from the FDA for ES-3000 in the treatment of CML. ES-3000 may also have efficacy in treatment of AML.

Join the Sage Healthcare mailing list

Your subscription could not be saved. Please try again.
Your subscription to the Sage Healthcare Newsletter has been successful.

Subscribe to our newsletter and stay updated.

© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026

Join the Sage Healthcare mailing list

Your subscription could not be saved. Please try again.
Your subscription to the Sage Healthcare Newsletter has been successful.

Subscribe to our newsletter and stay updated.

© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026

Join the Sage Healthcare mailing list

Your subscription could not be saved. Please try again.
Your subscription to the Sage Healthcare Newsletter has been successful.

Subscribe to our newsletter and stay updated.

© 2026. All rights reserved.